Information to Participate in Research Studies – by The National MS Society
NOTE: The COVID-19 pandemic may affect the status of the studies listed on this website. Trial recruitment or visits may…
Pregnant Women With MS Show Increased NfL
— Rise in neurofilament light during pregnancy, postpartum was independent of relapse by Judy George, Senior Staff Writer, MedPage Today September 28,…
Stuart Schlossman
MS treatment a step closer after drug shown to repair nerve coating
Side-effects of bexarotene rule out use but trial suggests other drugs may halt multiple sclerosis A MRI scan shows a…
Stuart Schlossman
Stephen L. Hauser, MD: Increasing Understanding of Disease Progression in MS
September 23, 2020 The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that…
Stuart Schlossman
Early Intensive MS Treatment Yields Better Outcomes Than Escalation Approach
September 23, 2020 Matt Hoffman Early intensive treatment was more effective in controlling disability progression over time compared with an…
Stuart Schlossman
Does obesity exacerbate brain lesion volume and atrophy in patients with multiple sclerosis?
Click HERE to Subscribe for the MS Beacon Newsletter Rachel Galioto 1, Ophira Berenholz 2, Zhini Wang 3, Devon S Conway 4, Sarah M Planchon 4, Stephen M Rao 5 Affiliations expand…
Stuart Schlossman
PRESS RELEASE: Genentech Expands Its Multiple Sclerosis Portfolio With Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus (ocrelizumab)
September 8, 2020 Phase III clinical trial program initiated for investigational medicine fenebrutinib, designed to be a highly selective and…
Stuart Schlossman
Personalizing Multiple Sclerosis Treatment: What Does the Future Hold? – This is for MS Practitioners
Click HERE to Subscribe for the MS Beacon Newsletter Intended Audience: Physicians (MS Specialists, Neurologists, Primary Care Providers), Nurses, Pharmacists, and…
Stuart Schlossman
Prescribed psychiatric medication among multiple sclerosis patients before and after disability pension: a register study with matched controls
Click HERE to Subscribe for the MS Beacon Newsletter Abstract Background: Many multiple sclerosis (MS) patients of working ages have psychiatric…
Stuart Schlossman
Rituximab More Effective Than Gilenya, Tecfidera, and Comparable to Tysabri, Study Finds
AUGUST 11, 2020 BY MARTA FIGUEIREDO Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod) and Tecfidera (dimethyl…
Stuart Schlossman
